Global Kinetics gains FDA approval.
Global Kinetics Corporation has received notification from the US Food and Drug Administration (FDA) of 510(k) clearance for its second generation technology – the PKG™-Watch.
The PKG™-Watch, also known as the Personal KinetiGraph™, is worn to assess Parkinson’s Disease symptoms. Blue Curve has worked closely with Global Kinetics in the development of the PKG™-Watch,leading to its successful FDA approval.
The Personal KinetiGraph is a wrist-worn device approved in the U.S. that automatically collects and records movement in Parkinson’s patient’s movements so that neurologists and other doctors can monitor any changes over time and tailor therapies accordingly. Doctors receive data from the PKG which assists in the diagnosis and treatment of Parkinson’s Disease and other movement disorders such as Huntington’s Disease or Restless Legs Syndrome.
Parkinson’s Disease is a chronic disease affecting approximately 70,000 Australians. As the disease presents differently across individuals, the PKG provides doctors with valuable data to ensure that patients receive the most responsive treatment according to their symptoms. The device can also prompt patients when it’s time to take medication and track compliance.
For more information visit